868 abstracts found.



Results filter

Combined targeting of Aurora B (AZD1152) and MEK1/2 (AZD6244) kinases leads to enhancement of anti-tumour effects in vivo

Year:

Session type:

Rajesh Odedra1, Simon P Heaton2, Armelle Logie1, Elizabeth Anderson1, Paul D Smith1, Robert W Wilkinson1

1AstraZeneca Pharmaceuticals, Macclesfield, UK, 2The Institute of Cancer Research, Sutton, UK


Phase I evaluation of radioimmunotherapy with 131I-CHT25 in patients with refractory IL2-receptor-expressing lymphomas

Year:

Session type:

Richard Begent2, Christopher McNamara2, Philip Ross1, James Ritchie1

1Cancer Research UK, London, UK, 2Royal Free Hospital, London, UK


Construction and characterisation of novel fusion toxin targeted to cancer (DT-SCF)

Year:

Session type:

Sirisha Potala, Rama Verma

Indian Institute of Technology Madras, Tamil Nadu, India


Efficacy and toxicities of a reduced dose sunitinib regimen in metastatic renal cell carcinoma

Year:

Session type:

Wei Seong Ooi1, Ko Ko Lin Thaw1, Valerie Khoo1, Vanessa Khoo1, Ravindran Kanesvaran1, Alexandre Chan3, Miah Hiang Tay1, Chee Keong Toh1, Min-Han Tan1

1National Cancer Centre Singapore, Singapore, 2National Cancer Centre Singapore, Singapore


Biological properties of the novel Chk1 inhibitor SAR-020106

Year:

Session type:

Paul Eve1, Mike Walton1, Angela Hayes1, Melanie Valenti1, Alexis De Haven Brandon1, Kathy Boxall1, Wynne Aherne1, Sue Eccles1, Gary Box1, Florence Raynaud1, David Williams2, Ian Collins1, John Reader2, Michelle Garrett1

1The Institute of Cancer Research, Surrey, UK, 2Sareum Ltd, Cambridge, UK


Investigating the link between diet and prostate cancer within the ProtecT trial

Year:

Session type:

Catherine Jameson1, Athene Lane1, Pauline Emmett1, Liz Down1, Marta Tazewell1, Steven Oliver4, Freddie Hamdy3, David Neal2, Jenny Donovan1

1University of Bristol, UK, 2Cambridge University Addenbrookes Hospital, UK, 3University of Oxford, UK, 4University of York, UK


A comparison of the UCLA Integrated Staging System (UISS) model and the Leibovich score in survival prediction for patients with non-metastatic clear cell renal cell carcinoma

Year:

Session type:

Tiffany Tang1, Min Tun Nay1, Myo Oo Nay1, Kamalakannan Srimalan1, Caroline Choong2, Vanessa Khoo1, Valerie Khoo1, Tsung Wen Chong2, Puay Hoon Tan2, Min-Han Tan1

1The National Cancer Centre, Singapore, 2Singapore General Hospital, Singapore


A neurofuzzy model to identify insignificant prostate cancer: development and validation using the ProtecT randomised controlled trial

Year:

Session type:

James Catto1, Maysam Abbod5, Derek Linkens1, Derek Rosario1, Jenny Donovan4, David Neal3, Freddie Hamdy2

1University of Sheffield, UK, 2University of Oxford, UK, 3University of Cambridge, UK, 4University of Bristol, UK, 5Brunel University, London, UK


A comparison of MicroRNA profiles in the circulating cells from men with locally confined and advanced prostate cancer

Year:

Session type:

Geetha Laxala1, Freddie Hamdy2, Stephane Larre2, James Catto1

1University of Sheffield, UK, 2University of Oxford, UK


Epigenetic regulation of MicroRNA in bladder cancer

Year:

Session type:

Hani Choudry, Helen Owen, James Catto

University of Sheffield, UK


The role of Akt in tumour cell survival post irradiation

Year:

Session type:

Oliver Sampson, Anne-Lucie Nugues, Eric O'Neill

University of Oxford, UK


Recognition of anxiety and depression in gynaecological cancer using the HAD Score

Year:

Session type:

Hannah Kither2, Jacki Routledge1, Meriel Burns1, Ric Swindell1, Susan Davidson1

1Christie Hospital NHS Foundation Trust, Manchester, UK, 2Manchester Royal Infirmary, UK


Needle oophropexy: a new simple technique for ovarian transposition prior to pelvic irradiation

Year:

Session type:

Waheed Gareer, Zeiad Gad

National Cancer Institute, Cairo University, Egypt


Radiotherapy-related heart damage in breast cancer patients is predicted by cutaneous telangiectasiae

Year:

Session type:

Chris Talbot1, George Tanteles1, Irene Peat1, Ahmed Osman1, Gerry McCann2, Steve Chan3, Julian Barwell1, R. Paul Symonds1

1University of Leicester, UK, 2University Hospitals of Leicester, Glenfield Hospital, UK, 3Nottingham University Hospitals NHS Trust, UK


A study of the relationship between drug efficacy/toxicity and platinum-DNA adduct formation in pre- and post-infusion lymphocyte samples from patients receiving platinum-based chemotherapy

Year:

Session type:

A L Thomas1, A Zayed2, J P Wood1, H Reid2, GDD Jones1, B L Sharp2

1University of Leicester, UK, 2Loughborough University, UK


Life-long vegetarianism and risk of colorectal cancer in India: a case-control study

Year:

Session type:

Raghib Ali1, Mohandas Mallath2, Valerie Beral1

1Oxford University, UK, 2Tata Memorial Centre, Mumbai, India


Gemcitabine with or without prophylactic weight-adjusted Dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)

Year:

Session type:

Anthony Maraveyas1, Justin Waters2, Rajarshi Roy3, David Propper4, David Fyfe5, Fiona Lofts6, Eric Gardiner1, Joseph Sgouros1, Kevin Wedgwood1

1The Queens Centre for Oncology & Hematology, Hull, UK, 2Kent Oncology Centre, Maidstone Hospital, UK, 3Diana Princess of Wales Hospital, Grimsby, UK, 4St Bartholomews Hospital,, London, UK, 5Royal Lancaster Infirmary, UK, 6St. Georges Hospital Medical School, London, UK


Array comparative genomic hybridisation analysis of colorectal cancer shows prognostically relevant differential patterns of DNA copy number alterations in microsatellite stable and unstable tumours

Year:

Session type:

George Poulogiannis1, Koichi Ichimura1, Suet Y Leung2, Siu T Yuen2, Rifat Hamoudi1, Feijun Luo1, David Harrison3, V Peter Collins1, Andrew Wyllie1, Mark Arends1

1University of Cambridge, UK, 2University of Hong Kong, Hong Kong, 3University of Edinburgh, UK


Unplanned hospital admissions as an early surrogate indicator of patient (pt) attrition in phase I trials

Year:

Session type:

Saoirse Dolly

The Institute of Cancer Research, London, UK


Identification of prognostic biomarkers for colorectal cancer

Year:

Session type:

Clare Foster, Naomi Willis, Joanne Robson, Christopher Hutchison

Durham University, UK


A novel role for Nutlin-3 in the mammalian DNA-damage response

Year:

Session type:

Jane Valentine, Sonia Kumar, Abdeladim Moumen

St George's Hospital, University of London, UK


Aspirin, non-steroidal anti-inflammatory drug and paracetamol use is associated with an increased risk of prostate cancer in a large, population-based, case-control study

Year:

Session type:

Ali Murad1, Liz Down1, George Davey Smith1, Jenny Donovan1, Janet Athene Lane1, Freddie Hamdy2, David Neal3, Richard Martin1

1University of Bristol, UK, 2John Radcliffe Hospital, Oxford, UK, 3University of Cambridge, UK


A two stage multicentre phase II study of Imatinib in the treatment of patients with c-kit positive metastatic uvEal Melanoma (ITEM)

Year:

Session type:

Ernie Marshall1, Carlos Escriu1, Paul Nathan4, S Danson5, M Marples6, Sarah E Coupland2, Catrin Tudur Smith3, Susanna Dodd3, Matthew Bickerstaff3, Bertil Damato2

1Clatterbridge Centre for Oncology, Merseyside, UK, 2Royal Liverpool University Hospital, UK, 3Liverpool Clinical Trials Unit, UK, 4Mount Vernon Hospital, Middlesex, UK, 5Weston Park Hospital, Sheffield, UK, 6St James University Hospital, Leeds, UK


Lifestyle intervention improves functional capacity in men on androgen deprivation therapy for prostate cancer

Year:

Session type:

Liam Bourke1, Helen Crank1, Amanda Daley3, Derek Rosario2, John Saxton1

1Sheffield Hallam University, UK, 2University of Sheffield, UK, 3University of Birmingham, UK


Plasma phytanic acid concentration and risk of prostate cancer

Year:

Session type:

Alison Price, Naomi Allen, Timothy Key

University of Oxford, UK


CAPP2 long term follow up: aspirin protects against hereditary cancer

Year:

Session type:

John Burn1, John Mathers1, Anne-Marie Gerdes1, Marie-Luise Bisgaard2, D. Gareth Evans3, Diana Eccles4, Annika Lindblom5, Finlay Macrae6, Eamonn Maher7, Jukka-Pekka Mecklin8, Gabriela Moeslein9, Sylviane Olschwang10, Raj Ramesar11, Hans Vasen12, Juul Wijnen13, Gail Barker1, Faye Elliott14, Henry Lynch15, D. Timothy Bishop14

1Newcastle University, UK, 2University of Copenhagen, Denmark, 3St Marys Hospital, Manchester, UK, 4University of Southampton, UK, 5Karolinska Hospital, Stockholm, Sweden, 6The Royal Melbourne Hospital, Melbourne, Australia, 7Birmingham Women's Hospital, UK, 8Jyvskyl Central Hospital, Finland, 9St. Josefs-Hospital Bochum-Linden, Germany, 10Institut Paoli Calmettes, Marseille, France, 11University of Cape Town, South Africa, 12Foundation for Detection of Hereditary Tumours, Leiden, Netherlands, 13Leiden University Medical Center, Netherlands, 14University of Leeds, UK, 15Creighton University School of Medicine, Omaha, USA


Small intestinal atypical carcinoid tumour with clear cell features: a case report and its differential diagnosis

Year:

Session type:

Jose Caduhada, Arlene De Luna

Philippine Heart Center, Quezon City, Philippines


Sensitisation of human colon cancer cell lines to TRAIL induced-apoptosis following inhibition of PI3K or HSP90

Year:

Session type:

Grazia Saturno, Paul Clarke, Paul Workman

The Institute of Cancer Research, Sutton, UK


Peripheral Neuropathy (PN) during and 12 months after Capecitabine and Oxaliplatin chemotherapy (CAPOX) for colorectal cancer

Year:

Session type:

Dawn Storey1, Maria Sakala2, Sally Clive2

1University of Edinburgh Cancer Research Centre, UK, 2Edinburgh Cancer Centre, UK


CD24 expression enhances cell migration and invasion and confers possible stem cell features in colorectal cancer lines

Year:

Session type:

Mohamed Ahmed, Darryl Jackson, Rashmi Seth, Mohammad Ilyas

School of Molecular Medical Sciences, Nottingham, UK


Randomised phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)

Year:

Session type:

Marc Peeters1, Tim Price2, Yevhen Hotko3, Andres Cervantes4, Michel Ducreux5, Thierry Andr6, Emily Chan7, Florian Lordick8, Alan Rong9, Jennifer Gansert9

1University Hospital Ghent, Belgium, 2Queen Elizabeth Hospital, Woodville, Australia, 3Uzhgorod National University, Ukraine, 4Hospital Clinico Universitario, Valencia, Spain, 5Institut Gustave Roussy, Villejuif, France, 6Hpital Piti-Salptrire, Paris, France, 7Vanderbilt University Medical Center, Tennessee, USA, 8Nationales Centrum fr Tumourerkrankungen, Heidelberg, Germany, 9Amgen Inc, California, USA


Development of an oral health related quality of life module: a presentation of phase I of three in the EORTC module development process

Year:

Session type:

Marianne Jensen Hjermstad1, Sheila Fisher2, Ourania Nicolatou-Galitis3, Joachim Weis4, Sebastian Montel5, Irma Verdonck6, Bente Herlofson7, Kristin Bjordal8, Petter Wilberg7

1Oslo University Hospital, Trondheim, Norway, 2University of Leeds, UK, 3University of Athens, Greece, 4University of Freiburg, Germany, 5Institut Curie, Paris, France, 6VU University Medical Centre, Amsterdam, Netherlands, 7University of Oslo, Norway, 8Oslo University Hospital, Norway


Randomised phase 3 study of panitumumab with FOLFOX compared to FOLFOX alone as 1st line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial

Year:

Session type:

James Cassidy1, Jean-Yves Douillard2, Salvatore Siena3, Josep Tabernero4, Ronald Burkes5, Mario Barugel6, Yves Humblet7, David Cunningham8, Michael Wolf9, Jennifer Gansert9

1Beatson Cancer Centre, Glasgow, UK, 2Centre Ren Gauducheau, Nantes, France, 3Ospedale Niguarda Ca Granda, Milan, Italy, 4Vall d'Hebrn University Hospital, Barcelona, Spain, 5Mount Sinai Hospital, Toronto, Canada, 6Hospital de Gastroenterologa, Buenos Aires, Argentina, 7Centre du Cancer de l'Universit Catholique de Louvain, Brussels, Belgium, 8The Royal Marsden NHS Foundation Trust, London, UK, 9Amgen Inc, California, USA


Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals perspectives

Year:

Session type:

Audrey Ardern-Jones, Regina Kenen, Elly Lynch, Rebecca Doherty, Rosalind Eeles

1The Royal Marsden NHS Foundation Trust, London, UK, 2The College of New Jersey Sociology and Anthropology, New Jersey, USA, 3The Royal Melbourne Hospital, Melbourne, Australia, 4The Institute of Cancer Research, Surrey, UK, 5The Institute of Cancer Research; The Royal Marsden NHS Foundation Trust, Surrey, UK


Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study

Year:

Session type:

Jim Paul1, Jim Cassidy1, Rachel Midgley2, Tim Iveson3, Andrea Harkin1, Michelle Masterson2

1University of Glasgow, UK, 2University of Oxford, UK, 3Southampton University Hospitals NHS Trust, UK


Translation and validation of Social Difficulties Inventory (SDI-21) into Urdu, Punjabi and Hindi

Year:

Session type:

Naheed Hanif2, Nimarta Dharni2, Sangeeta Chattoo3, Galina Velikova1, Karl Atkin3, Chris Bradley2, Dan Stark1, Penny Wright1

1University of Leeds, UK, 2Institute for Health Research, Bradford Royal Infirmary, UK, 3University of York, UK


Lifestyle intervention improves exercise capacity and symptoms of fatigue in bowel cancer survivors: pilot RCT

Year:

Session type:

Liam Bourke1, Georgia Thompson2, Amanda Daley3, Ian Adam2, Andrew Shorthouse1, John Saxton1

1Sheffield Hallam University, UK, 2Northern General Hospital, UK, 3University of Birmingham, UK


Public attitudes to cancer: emotional and rational beliefs

Year:

Session type:

Alice Simon, Kathryn Robb, Anne Miles, Lauren Matheson, Claudia Redekker, Jane Wardle

University College London, UK


Meat, poultry and fish and risk of colorectal cancer: pooled analysis of data from the UK Dietary Cohort Consortium

Year:

Session type:

Elizabeth Spencer1, Timothy Key1, Paul Appleby1, Christina Dahm2, Ian Fentiman3, Tasnime Akbaraly4, Eric Brunner4, Victoria Burley5, Janet Cade5, Darren Greenwood5, Alison Stephen2, Gita Mishra4, Diana Kuh4, Robert Luben2, Marleen Lentjes2, Angela Mulligan2, Kay-Tee Khaw2, Sheila Rodwell2

1University of Oxford, UK, 2University of Cambridge, UK, 3Guy's Hospital, London, UK, 4University College London, UK, 5University of Leeds, UK


The Bus: an interim evaluation

Year:

Session type:

Rachel Iredale, Andrew Hayward, Catherine Botting, Debbie Marsden

Cardiff University, UK


Daytime napping and cancer risk: sleep patterns, prevalent disease or unhealthy lifestyles?

Year:

Session type:

Benjamin Cairns, Ruth Travis, Gillian Reeves, Valerie Beral

University of Oxford, UK


Thrombocytopenia leading to sub-optimal treatment in glioblastoma

Year:

Session type:

Gurdip Azad, Elena Wilson, Katharine Pigott, Robert Bradford

Royal Free Hospital, London, UK


Parameters predicting survival outcome in glioblastoma

Year:

Session type:

Gurdip Azad, Elena Wilson, Katharine Pigott, Robert Bradford

Royal Free Hospital, London, UK


Clinical outcomes of retrosigmoid approach for vestibular schwannoma

Year:

Session type:

Bong Jin Park, Yong Jin Lim, Cheol Eon Park, Jae Yong Byun, Moon Suh Park, Chang Il Cha, Seung Geun Yeo

KyungHee University, Seoul, Korea


Invasive behaviour of GBM derived cell lines is not defined by NG2 status

Year:

Session type:

Sara Dietz, Colin Watts

University of Cambridge, UK


Rho-GTPase signaling and the vascular disrupting activities of combretastatin A-4-phosphate

Year:

Session type:

Chryso Kanthou, Leigh Williams, Gillian Tozer

University of Sheffield, UK


Homologous recombination and ovarian cancer: role of developing a functional assay

Year:

Session type:

Asima Mukhopadhyay, Yvette Drew, Evan Mulligan, Sarah Wilkinson, Suzanne Kyle, Ahmed Elatter, Nicola Curtin, Richard Edmondson

Northern Institute for Cancer Research, Newcastle University, UK


Abstract withdrawn

Year:

Session type:


Novel anticancer drug combinations exploiting arginine depletion with ADI-PEG 20 in the treatment of ASS1-negative malignant mesothelioma

Year:

Session type:

Barbara Delage1, Claude Chelala1, Dean Fennell2, Nick Lemoine1, Peter Szlosarek1

1Institute of Cancer, Barts and The London, London, UK, 2Centre for Cancer Research and Cell Biology, Belfast, UK


The synthesis of novel G-quadruplex ligands and Host-Guest binding evaluation using DOSY NMR

Year:

Session type:

Adam Le Gresley

Kingston University, Kingston-Upon-Thames, UK